Identification of small molecule therapies such as tyrosine kinase inhibitors (TKIs) and B cell lymphoma‐2 (Bcl‐2) inhibitors has enabled effective therapy in CML, AML, and systemic mastocytosis [6, 7, 8, 9, 10]. Here, BCL2 is linked to acute myeloid leukemia.